Related Experiment Videos
[Therapeutic efficacy of azithromycin in pediatrics]
1Department of Pediatrics, Kobe Central Municipal Hospital.
Insights
Azithromycin (AZM) demonstrated high efficacy in treating bacterial infections in pediatric patients, with excellent or good ratings in all cases. The antibiotic showed a high eradication rate and was well-tolerated, proving useful in this population.
Area of Science:
- Pediatric Infectious Diseases
- Pharmacology
- Microbiology
Background:
- Azithromycin (AZM) is a novel azalide antibiotic.
- Bacterial infections pose a significant health concern in pediatric populations.
Purpose of the Study:
- To evaluate the therapeutic efficacy and safety of Azithromycin in pediatric patients with bacterial infections.
- To assess the eradication rates of common bacterial pathogens in children treated with AZM.
Main Methods:
- A cohort of 12 pediatric patients with various bacterial infections received Azithromycin at a standard dose (10 mg/kg daily for 3 days).
- Clinical outcomes were assessed, and bacterial strains (Streptococcus pyogenes, Haemophilus influenzae, Haemophilus parainfluenzae) were isolated and their eradication determined.
- Adverse reactions and laboratory test values were monitored.
Main Results:
- Azithromycin was rated "excellent" in 8 cases and "good" in 4 cases, indicating high clinical efficacy.
- An 88.9% bacterial eradication rate was achieved for isolated strains.
- No adverse reactions were reported; one case of eosinophilia was noted as an abnormal laboratory finding.
Conclusions:
- Azithromycin is a useful and effective antibiotic for treating bacterial infections in pediatric patients.
- The drug demonstrated a favorable safety profile and good compliance in the studied pediatric population.
Abstract:
Azithromycin (AZM), a newly developed azalide antibiotic, was administered at a standard dose of 10 mg/kg once daily for 3 days to pediatric patients with bacterial infections and the therapeutic efficacy of AZM was investigated. 1. A total of 12 patients with the following diseases was evaluated: pharyngitis in two, tonsillitis in four, bronchitis in one, Mycoplasma pneumonia in one, scarlet fever in two and enteritis in two. The drug was rated "excellent" in eight cases and "good" in four. 2. Eleven strains were isolated from patients: five strains of Streptococcus pyogenes, four strains of Haemophilus influenzae, and two strains of Haemophilus parainfluenzae. Isolated bacteria were eradicated in eight strains and persisting in one, resulting in 88.9% in eradication rate. No follow-up examinations in post-treatment were performed in two cases. 3. No adverse reaction was reported, while one case of eosinophilia was noted as an abnormal laboratory test value. 4. As far as compliance is concerned, patients claimed that the formulation of the drug is "easy to take" or "ordinary". With the results presented as above, we have concluded that AZM is a useful antibiotic in pediatric patients with bacterial infections.